These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38000932)

  • 1. Reply to Eduard Roussel, Riccardo Bertolo, Chiara Ciccarese, et al's Letter to the Editor re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
    Abel EJ; Master VA; Spiess PE; Raman JD; Shapiro DD; Sexton WJ; Zemp L; Patil D; Lauer K; Allen GO; Matin SF; Karam JA
    Eur Urol Oncol; 2024 Apr; 7(2):302-303. PubMed ID: 38000932
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: E. Jason Abel, Viraj A. Master, Philippe E. Spiess, et al. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features. Eur Urol Oncol. 2023;6:266-274.
    Roussel E; Bertolo R; Ciccarese C; Marandino L; Marchioni M; Campi R; Albersen M;
    Eur Urol Oncol; 2024 Apr; 7(2):304-305. PubMed ID: 37981494
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End.
    Massari F; Di Nunno V; Santoni M; Gatto L; Mollica V; Porta C
    Eur Urol Oncol; 2019 Sep; 2(5):603-604. PubMed ID: 31411982
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Kunlin Yang, Xuesong Li, and Liqun Zhou's Letter to the Editor re: Eduard Roussel, Giovanni Tasso, Riccardo Campi, et al. Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter Collaboration. Eur Urol 2021;79:133-40.
    Roussel E; Tasso G; Albersen M
    Eur Urol; 2021 Jul; 80(1):e32. PubMed ID: 33941401
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Daniel D. Shapiro, Jose A. Karam, Viraj A. Master, et al.'s Letter to the Editor re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610.
    Yip W; Ghoreifi A; Djaladat H
    Eur Urol Oncol; 2023 Dec; 6(6):637. PubMed ID: 37316397
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Zhenjie Wu and Linhui Wang's Letter to the Editor re: Riccardo Bertolo, Riccardo Autorino, Giuseppe Simone, et al. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). Eur Urol 2018;74:226-32.
    Bertolo R; Autorino R
    Eur Urol; 2018 Dec; 74(6):e147-e148. PubMed ID: 30193967
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Lorenzo Marconi, Steven MacLennan, Thomas B.L. Lam, et al's Letter to the Editor re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017;71:606-17.
    Derweesh IH; Mir MC; Autorino R
    Eur Urol; 2017 Sep; 72(3):e61-e62. PubMed ID: 28642021
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Takeshi Takahashi's Letter to the Editor re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol 2021;80;760-2. Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki: Re-envisioning the Value of Clinical Research to Foster the Progress of Evidence-based Urology: The Case of Partial Nephrectomy for cT2 Renal Masses.
    Campi R; Bertolo R; Minervini A;
    Eur Urol; 2022 Feb; 81(2):e46-e47. PubMed ID: 34887115
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Eduard Roussel, Giovanni Tasso, Riccardo Campi, et al. Surgical Management and Outcomes of Renal Tumors Arising from Horseshoe Kidneys: Results from an International Multicenter Collaboration. Eur Urol 2021;79:133-40.
    Yang K; Li X; Zhou L
    Eur Urol; 2021 Jul; 80(1):e30-e31. PubMed ID: 33941400
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Pranav Sharma, Asad Sawar and Philippe Spiess' letter to the editor re: re: Craig Rogers, Ravi Barod, Scott Schwartz, Mani Menon. Endovascular extraction of caval tumor thrombus to facilitate minimally invasive cytoreductive nephrectomy for metastatic kidney cancer. Eur Urol 2015;68:167-8.
    Rogers CG; Barod R; Schwartz S; Menon M
    Eur Urol; 2015 Oct; 68(4):e81. PubMed ID: 26004799
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to E. Jason Abel Letter to the Editor re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660-73.
    Marconi L; Lam TB; Bex A; Ljungberg B; Volpe A
    Eur Urol; 2016 Jun; 69(6):e119-20. PubMed ID: 26776936
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
    Shapiro DD; Karam JA; Master VA; Zemp LW; Sexton WJ; Matin SF; Spiess PE; Jason Abel E
    Eur Urol; 2023 Aug; 84(2):e55-e56. PubMed ID: 37149462
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Riccardo Bertolo, Riccardo Autorino, Giuseppe Simone, et al. Outcomes of Robot-assisted Partial Nephrectomy for Clinical T2 Renal Tumors: A Multicenter Analysis (ROSULA Collaborative Group). Eur Urol 2018;74:226-32.
    Wu Z; Wang L
    Eur Urol; 2018 Dec; 74(6):e145-e146. PubMed ID: 30193968
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Riccardo Campi, Riccardo Bertolo, Andrea Minervini, European Association of Urology Young Academic Urologists Renal Cancer Working Group. Re: Partial Versus Radical Nephrectomy in Clinical T2 Renal Masses. Klett DE, Tsivian M, Packiam VT, et al. Int J Urol. 2021;28:1149-54. Eur Urol. 2021;80:760-2: Partial Nephrectomy for T2 Kidney Cancer Might Violate the Declaration of Helsinki.
    Takahashi T
    Eur Urol; 2022 Feb; 81(2):e44-e45. PubMed ID: 34887116
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Chen Cai, Huamao Ye, and Bing Liu's letter to the editor re: Francesco Greco, Riccardo Autorino, Koon H. Rha, et al. Laparoendoscopic single-site partial nephrectomy: a multi-institutional outcome analysis. Eur Urol 2013;64:314-22.
    Greco F; Autorino R
    Eur Urol; 2013 Aug; 64(2):e33-4. PubMed ID: 23628494
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Alessia Cimadamore, Marina Scarpelli, Liang Cheng, et al's Letter to the Editor, re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019, 76:871.
    Sighinolfi MC; Rocco B
    Eur Urol; 2020 May; 77(5):e128-e129. PubMed ID: 32067794
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Nikolaos Grivas, Sanchia Goonewardene, Wouter Everaerts, Nikolaos Kalampokis's Letter to the Editor re: Andrea Mari, Riccardo Tellini, Francesco Porpiglia, et al. Perioperative and Mid-term Oncological and Functional Outcomes After Partial Nephrectomy for Complex (PADUA Score ≥10) Renal Tumors: A Prospective Multicenter Observational Study (the RECORD2, Project). Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2020.07.004.
    Mari A; Tellini R; Ficarra V; Carini M; Minervini A;
    Eur Urol Focus; 2021 Sep; 7(5):1212-1213. PubMed ID: 33384273
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
    Ghoreifi A; Djaladat H
    Eur Urol; 2023 Aug; 84(2):e53-e54. PubMed ID: 37149463
    [No Abstract]   [Full Text] [Related]  

  • 20. The Selection for Cytoreductive Nephrectomy (SCREEN) Score: Improving Surgical Risk Stratification by Integrating Common Radiographic Features.
    Abel EJ; Master VA; Spiess PE; Raman JD; Shapiro DD; Sexton WJ; Zemp L; Patil D; Lauer K; Allen GO; Matin SF; Karam JA
    Eur Urol Oncol; 2024 Apr; 7(2):266-274. PubMed ID: 37442673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.